FIRST LIGHT

23 May 2024

RESEARCH

JK CEMENT | TARGET: Rs 4,538 | +17% | BUY

Focused on growth; earnings intact; upgrade to BUY

BOB ECONOMICS RESEARCH | RBI DIVIDEND

Record high

SHREE CEMENT | TARGET: Rs 27,438 | +7% | HOLD

Cost savings key driver of performance; valuations pricey

BANDHAN BANK | TARGET: Rs 222 | +21% | BUY

In line with recovery plan

ERIS LIFESCIENCES | TARGET: Rs 1,200 | +32% | BUY

Strong revenue growth; integration ongoing

GREENPLY INDUSTRIES | TARGET: Rs 320 | +24% | BUY

Misses estimate on weak plywood margin; upbeat outlook

Daily macro indicators

Indicator	20-May	21-May	Chg (%)
US 10Y yield (%)	4.44	4.41	(3bps)
India 10Y yield (%)	7.09	7.08	(1bps)
USD/INR	83.33	83.31	0.0
Brent Crude (US$/bbl)	83.7	82.9	(1.0)
Dow	39,807	39,873	0.2
Hang Seng	19,636	19,221	(2.1)
Sensex	74,006	73,953	(0.1)
India FII (US$ mn)	**16-May**	**17-May**	**Chg ($ mn)**
FII-D	109.7	107.6	(2.2)
FII-E	(74.5)	261.2	335.8

Source: Bank of Baroda Economics Research

SUMMARY

JK CEMENT

- Q4 revenue grew 10% YoY to Rs 29.4bn as grey cement volumes gained 13% YoY/QoQ; realisation resilient YoY with 1% drop
- EBITDA spiked to Rs 5.5bn with healthy margins of 18.6%, on healthy cost savings as cost dropped 7%/1% YoY/QoQ
- We raise our FY26E EBITDA by +4% (FY25 no change) and value JKCE at 14x EV/EBITDA FY26E earnings; upgrade to BUY with TP of Rs 4,538

Click here **for the full report.**

BOBCAPS Research
research@bobcaps.in

INDIA ECONOMICS: RBI DIVIDEND

RBI declared a record Rs. 2.11 lakh crores surplus transfer to the government in FY25, compared with Rs. 87,416 crores in FY24. This was also much higher than both the budgeted (Rs. 1.02 lakh crores, including dividend from banks and FIs) and street estimates of ~Rs. 1 lakh crores surplus. The higher than anticipated surplus can be attributed to higher interest income led by an increase in both global as well as domestic yields. There were also revaluation gains on forex reserves unlike in 2022. The higher surplus will have a positive impact on government finances.

Click here for the full report.

SHREE CEMENT

- Q4 revenue growth of 7% YoY backed entirely by steady 7% volume as realisations stay listless
- Operating cost savings of ~10% YoY boost EBITDA margin by 730bps YoY to 26.0%
- Current valuations at 15x FY26E EV/EBITDA prices in performance; maintain earnings and HOLD rating with revised TP of Rs 27,438

Click here for the full report.

BANDHAN BANK

- Healthy business growth, improved asset quality and higher other income supported topline; increased provision dragged PAT
- Sustainability of margin, improvement in asset quality and smooth transition of top management would be key to watch
- PAT lowered on revised growth estimates but recent price correction factored into major negatives; retain BUY with TP of Rs 222 (vs. Rs 270)

Click here for the full report.

ERIS LIFESCIENCES

- ERIS posted strong revenue performance in Q4 with a beat of 8%, but EBITDA came below BBG consensus due to higher opex and one-offs
- Expects to reduce debt by Rs 4bn in FY25 and lower it to ~ Rs 20bn by FY26 from ~Rs 30bn in FY24
- We expect ERIS to post 23% earnings CAGR over FY24-26E. Revise TP to Rs 1,200 (from Rs 955) based on 15x FY26E EV/EBITDA

Click here for the full report.

GREENPLY INDUSTRIES

- MTLM missed our EBITDA estimate by 16% in Q4 on sharper-than-expected contraction in plywood margin on high timber prices
- Management guided for a positive outlook on plywood and MDF even in challenging market conditions
- Maintain BUY; raise TP by 7% to Rs 320 on strong earnings growth prospects (51% CAGR over FY24-FY26E) and reasonable valuations

Click here for the full report.

BUY
TP: Rs 4,538 | ▲ 17%

JK CEMENT | Cement | 22 May 2024

Focused on growth; earnings intact; upgrade to BUY

- Q4 revenue grew 10% YoY to Rs 29.4bn as grey cement volumes gained 13% YoY/QoQ; realisation resilient YoY with 1% drop
- EBITDA spiked to Rs 5.5bn with healthy margins of 18.6%, on healthy cost savings as cost dropped 7%/1% YoY/QoQ
- We raise our FY26E EBITDA by +4% (FY25 no change) and value JKCE at 14x EV/EBITDA FY26E earnings; upgrade to BUY with TP of Rs 4,538

Milind Raginwar
research@bobcaps.in

Double-digit revenue growth in challenging quarter: JKCE reported 10%/6% YoY/QoQ standalone revenue growth to Rs 29.4bn in Q4FY24. Grey cement volumes at ~4.7mn tonnes rose ~13% YoY/QoQ and realisations were down 2%/5% YoY/QoQ to Rs 4,928/t. White cement volumes (including putty) fell ~2% YoY/QoQ to 0.42mt and realisation declined 2% YoY but grew 2.4% QoQ to Rs 12,556/t.

Cost savings drove margins by 500bps: Operating cost savings continued with 7%/2% YoY/QoQ rise to Rs 4,697/t as raw material-adjusted energy cost dropped 23% (-3% QoQ) to Rs 1,907/t due to reduced pet coke prices. Logistics cost rose 2%/-1% YoY/QoQ to Rs 1,274/t owing to added lead distance to service new markets and busy season surcharge. Other expenditure jumped 15%/12% YoY/QoQ owing to the Rs150mn each spent on branding expenditure and technology shift from SAP. This helped EBITDA jump 50% YoY to Rs 5.5bn (-10% QoQ) with strong margin gain of 500bps YoY to 18.6%. EBITDA/t was up 35% YoY to Rs 1,075/t.

Expansion plans on track: JKCE's 1.5mtpa greenfield Ujjain expansion (grinding unit) is stabilising post commissioning in Q3FY24 and the 2mt greenfield Prayagraj grinding unit (GU) is due by Q2FY25. JKCE has announced a 3.3mt clinker line-II at Panna (with 1mt GU) to be completed by Q2/Q3 FY26. The 3mt grinding unit in Bihar and 1mt each in Hamirpur and Prayagraj will be completed by 2HFY26. The total estimated project cost is ~Rs 28.5bn. An 18MW WHRS unit at Karnataka is expected to be commissioned by Q1FY25 and benefits reflected from Q2FY25.

Poised to grow, upgrade to BUY: We maintain our FY25 estimates, but raise our FY26E EBITDA by +4%, modelling in an EBITDA/PAT CAGR of 36%/34% over FY23-FY26. To factor in higher depreciation and interest payment post capex execution, EPS growth is projected to be relatively slower in FY26. Our TP rises to Rs 4,538 (from Rs 4,121) as we now value JKCE at 14x (from 13x) EV/EBITDA FY26E earnings. This is at a premium to its long-term average due to JKCE's healthy growth outlook with timely capex, improving earnings quality, cushioning of white segment earnings and less balance sheet stress in capex phase. We upgrade JKCE to BUY from HOLD. At our TP, JKCE trades at replacement cost of ~Rs13bn.

Key changes

Target	Rating
▲	▲

Ticker/Price	JKCE IN/Rs 3,890
Market cap	US$ 3.7bn
Free float	54%
3M ADV	US$ 8.1mn
52wk high/low	Rs 4,575/Rs 2,893
Promoter/FPI/DII	46%/16%/22%

Source: NSE | Price as of 21 May 2024

Key financials

Y/E 31 Mar	FY24P	FY25E	FY26E
Total revenue (Rs mn)	1,09,181	1,26,016	1,47,678
EBITDA (Rs mn)	20,050	23,914	27,835
Adj. net profit (Rs mn)	8,361	11,199	13,519
Adj. EPS (Rs)	108.2	144.9	175.0
Consensus EPS (Rs)	108.2	133.6	162.3
Adj. ROAE (%)	17.0	19.1	19.4
Adj. P/E (x)	35.9	26.8	22.2
EV/EBITDA (x)	17.2	13.7	9.5
Adj. EPS growth (%)	48.6	33.9	20.7

Source: Company, Bloomberg, BOBCAPS Research | P – Provisional

Stock performance



Source: NSE

RBI DIVIDEND

22 May 2024

Record high

Dipanwita Mazumdar | Aditi Gupta
Economist

RBI declared a record Rs. 2.11 lakh crores surplus transfer to the government in FY25, compared with Rs. 87,416 crores in FY24. This was also much higher than both the budgeted (Rs. 1.02 lakh crores, including dividend from banks and FIs) and street estimates of ~Rs. 1 lakh crores surplus. The higher than anticipated surplus can be attributed to higher interest income led by an increase in both global as well as domestic yields. There were also revaluation gains on forex reserves unlike in 2022. The higher surplus will have a positive impact on government finances.

This is positive in terms of maintaining the targeted fiscal deficit. Thus, the additional Rs 1 lakh crore gives government the headroom to either cut back on its gross borrowing from the market, putting lesser pressure on domestic yields, or to increase its thrust towards capex. The main budget post elections will throw better light on the same. Overall, this is likely to have a positive impact on government yields. We expect 10Y yield to go below 7% in the coming months. Frontloading by FPIs due to inclusion in the global bond index will further lend support.

What has led to record high surplus: conjectures?

RBI has transferred a record high dividend to the government for accounting year 2023-24. This is far higher than budgeted amount of Rs 1.02 lakh crore for FY25. This Rs 1.02 lakh crore is also inclusive of Dividend transfer of Nationalised Banks & Financial Institutions. Thus, from RBI itself a windfall gain has been received. This level of high transfer of surplus was last witnessed in 2018-19. A result of such unexpected increase could be higher interest income from foreign securities, exchange gain/loss from foreign exchange transactions. The other part of in “other income” may be due to some rebalancing of provisions no longer required due to write-back of excess risk provision from Contingency Fund.

Fig 1. RBI transfer of surplus has increased substantially



Source: RBI, Bank of Baroda Research, Note: Accounting year

HOLD
TP: Rs 27,438 | ⮝ 7%

SHREE CEMENT | Cement | 22 May 2024

Cost savings key driver of performance; valuations pricey

- **Q4 revenue growth of 7% YoY backed entirely by steady 7% volume as realisations stay listless**
- **Operating cost savings of ~10% YoY boost EBITDA margin by 730bps YoY to 26.0%**
- **Current valuations at 15x FY26E EV/EBITDA prices in performance; maintain earnings and HOLD rating with revised TP of Rs 27,438**

Milind Raginwar
research@bobcaps.in

Volume-led revenue growth: SRCM's revenue grew 7% YoY (+4% QoQ) to Rs 51bn in Q4FY24 backed entirely by steady volume growth of 7% YoY/QoQ to 9.5mn tonnes, while realisations stayed listless at Rs 4,930/t. Higher volumes were aided by better capacity utilisation at 79% (from 77% in Q4FY23/Q3FY24).

Cost savings drive EBITDA: SRCM's EBITDA margin expanded 730bps/80bps YoY/QoQ to 26.0% and EBITDA/t rose 40% YoY on a weak base (flat QoQ) to Rs 1,340/t driven by energy and logistics cost savings. Energy costs declined 14% YoY (+9% QoQ) to Rs 1,520/t due to a 28% YoY reduction in fuel cost to Rs 1.82/kcal (from Rs2.53/kcal in 4QFY24), whereas logistics cost fell 5% YoY (flat QoQ) to Rs 1,096/t following a reduction in lead distance of ~20km. Total operating cost dipped 10%/4% YoY/QoQ to Rs 3,958/t. Power EBITDA came in at Rs 400mn.

Capacity expansion plans on schedule: The 3mt integrated cement unit in Guntur (Andhra Pradesh) was operational in Apr'24 taking SCRM's total capacity to 56mt by 1QFY25, which management expects to rise further to 62mt in FY25. SRCM expects to add ~9mt of capacity by FY25-end.

Earnings retained: We maintain our EBITDA estimates for FY25 despite weak 1HFY25 expectations owing to capacity addition by SRCM in FY24 going into full effect. We retain our FY26 EBITDA estimate as there is another strong leg of capacity addition in FY25. Our EPS estimates remain unchanged. We now pencil in a revenue/EBITDA/PAT CAGR of 15%/30%/32% over FY23-FY26E.

Maintain HOLD on expensive valuations: We maintain a HOLD rating as current valuations of 15x FY26E EV/EBITDA appear pricey given SRCM's inconsistent focus on brand vs growth, presence in the less remunerative southern and eastern regions of India and limited cost savings levers till FY26. We lower our TP to Rs 27,438 (Rs27,836) while valuing the stock at 15x FY26E EV/EBITDA – 2.25x over the industry replacement cost. Focus back on volume growth in Q4FY26 is a positive as pushing volume growth may be challenging in the regions of operations.

Key changes

Target	Rating
▼	◄ ►

Ticker/Price	SRCM IN/Rs 25,679
Market cap	US$ 11.3bn
Free float	37%
3M ADV	US$ 13.7mn
52wk high/low	Rs 30,738/Rs 22,606
Promoter/FPI/DII	63%/13%/12%

Source: NSE | Price as of 22 May 2024

Key financials

Y/E 31 Mar	FY24P	FY25E	FY26E
Total revenue (Rs mn)	1,95,855	2,23,703	2,48,515
EBITDA (Rs mn)	43,635	51,497	56,647
Adj. net profit (Rs mn)	24,684	26,618	30,234
Adj. EPS (Rs)	684.2	737.7	838.0
Consensus EPS (Rs)	684.2	733.0	840.0
Adj. ROAE (%)	12.8	12.5	12.9
Adj. P/E (x)	37.5	34.8	30.6
EV/EBITDA (x)	19.1	16.1	18.1
Adj. EPS growth (%)	85.9	7.8	13.6

Source: Company, Bloomberg, BOBCAPS Research | P – Provisional

Stock performance



Source: NSE

BUY
TP: Rs 222 | ⮝ 21%

BANDHAN BANK | Banking | 22 May 2024

In line with recovery plan

- **Healthy business growth, improved asset quality and higher other income supported topline; increased provision dragged PAT**
- **Sustainability of margin, improvement in asset quality and smooth transition of top management would be key to watch**
- **PAT lowered on revised growth estimates but recent price correction factored into major negatives; retain BUY with TP of Rs 222 (vs. Rs 270)**

Ajit Agrawal
research@bobcaps.in

Healthy business growth: Bandhan Bank maintained healthy business growth in Q4, wherein deposits growth (25% YoY) outpaced loan growth (16% YoY) leading to NII growth of 16%. Loan book growth was driven by Commercial Banking which grew 34% YoY, while the EEB division grew 10% YoY and retail remained flat over the same period. On the liability side, deposits was mainly driven by term deposits (30% YoY), while CASA grew 18% YoY leading to 97bps QoQ improvement in CASA ratio to 37%. Management guided for business growth of 18%, but deposits growth to continue to outpace loan.

NIM guidance maintained: Despite a rise in deposits cost, the bank reported NIM of 7.6% (7.2% in Q3) aided by higher yield and lower slippages. Other income increased 27% QoQ supported by total income. However, higher opex was on the back of Rs 1.1bn in one-off expenses leading to PPOP growth of 2% YoY (11% QoQ). Management indicated that recent investments towards technology and branch expansion would bring volume leverage to support bottomline growth.

Asset quality key: Slippages improved in Q4 to Rs 10.2bn vs. Rs 13.9bn in Q3, however the bank's strategic decision to write off Rs 38.5bn of stressed assets led to higher provision (jumped 160% QoQ) and dragged PAT to Rs 0.5bn (down 92% QoQ). Higher write-off helped the bank improve overall asset quality, wherein GNPA/NNPA stood at 3.8%/1.1% vs. 7%/2.2% in Q3. Overall SMA book improved to Rs 12.6bn from Rs 19.1bn in Q3 and management expects credit cost to improve to 1.8%-2% over FY25 from 5.8% in Q4.

Maintain BUY: Considering ongoing business dynamics, we trim the loan book estimate by 4%, but increase the deposit estimate by 7%/6% over FY25/26 leading to lower PAT estimate of 6% each for the same period. Baking in gradual improvement in asset quality and potential for improvement in operational costs and stable margins, we expect the overall return ratios to improve and further price correction factored into the major negatives, while a smooth management transition would be key to watch. We lower our valuation to 1.3x FY26E ABV, from 1.6x, and revise our TP to Rs 222 (Rs 270 earlier). Retain BUY.

Key changes

Target	Rating
▼	◄►

Ticker/Price	BANDHAN IN/Rs 184
Market cap	US$ 3.6bn
Free float	60%
3M ADV	US$ 32.7mn
52wk high/low	Rs 272/Rs 170
Promoter/FPI/DII	40%/31%/12%

Source: NSE | Price as of 21 May 2024

Key financials

Y/E 31 Mar	FY24P	FY25E	FY26E
NII (Rs mn)	103,256	121,892	145,373
NII growth (%)	11.5	18.0	19.3
Adj. net profit (Rs mn)	22,296	37,269	45,236
EPS (Rs)	13.8	23.1	28.1
Consensus EPS (Rs)	13.8	22.5	27.0
P/E (x)	13.3	8.0	6.6
P/BV (x)	1.4	1.2	1.0
ROA (%)	1.3	1.9	2.0
ROE (%)	10.8	16.0	16.8

Source: Company, Bloomberg, BOBCAPS Research | P – Provisional

Stock performance



Source: NSE

BOBCAPS
TRUST | INNOVATION | EXCELLENCE

BUY
TP: Rs 1,200 | ▲ 32%

ERIS LIFESCIENCES | Pharmaceuticals | 22 May 2024

Strong revenue growth; integration ongoing

- **ERIS posted strong revenue performance in Q4 with a beat of 8%, but EBITDA came below BBG consensus due to higher opex and one-offs**
- **Expects to reduce debt by Rs 4bn in FY25 and lower it to ~ Rs 20bn by FY26 from ~Rs 30bn in FY24**
- **We expect ERIS to post 23% earnings CAGR over FY24-26E. Revise TP to Rs 1,200 (from Rs 955) based on 15x FY26E EV/EBITDA**

Saad Shaikh
research@bobcaps.in

Robust revenue growth: ERIS's revenue grew strongly at 37% YoY to Rs 5.5bn in Q4FY24 and 19% in FY24 to Rs 20.1bn, supported by traction in new therapies and acquired businesses. In secondary terms, ERIS grew at 14.4% in Q4 as per the IQVIA and outperformed Indian Pharma market (IPM) by 507bps. The newly-acquired business of Swiss Parenterals contributed Rs 550mn to revenue in Q4. ERIS highlighted the visibility of 20+ first-in-market launches through the R&D pipeline. It expects the domestic branded formulations business to clock 12-14% organic growth for FY25. With its diversification exercise (FY22-24), ERIS's concentration in top-3 therapies has reduced to 54% from 80%. Emerging therapies (Derma, Insulins, WHC, CNS, Onco, Nephro) now account for ~40%.

Higher opex and one-offs impact margins: EBITDA for the quarter grew 25% YoY to Rs 1.5bn, 16% below Bloomberg expectations due to higher opex, one-offs and lower capacity utilisation of the newly commissioned plant. Gross/EBITDA margin came in at 78.5%/26.9%, contractions of 340bps/260bps YoY. The gross margin contraction was due to the change in product mix. We expect ERIS to maintain EBITDA margin at 34-35% due to integration-related costs. The excess operational cost associated with the Ahmedabad plant will be normalised by the end of 4QFY25.

Earnings call highlights: (1) Organic revenue growth of 12-14% for FY25 on domestic branded formulation base business of FY24; expect to maintain EBIDTA margin of 36%. (2) Good visibility of 20+ "first-in-market" launches through own R&D pipeline. (3) Capex for new "fill-finish" blocks of hormones and insulins at Ahmedabad facility amounting to Rs 700mn-800mn. (4) There was a one-time expense of Rs 210m related to SAP implementation, deal-related expenses, and donations.

Maintain BUY; raise TP to Rs 1,200: We expect ERIS to post 23% earnings growth over FY24-26E and EBITDA margin in the range of 34-35%. We apply 15x FY26E EV/EBITDA – an implied P/E of 25x – to arrive at a revised TP of Rs 1,200 from Rs 955. Reiterate BUY.

Key changes

Target	Rating
▲	◄ ►

Ticker/Price	ERIS IN/Rs 908
Market cap	US$ 1.5bn
Free float	29%
3M ADV	US$ 1.6mn
52wk high/low	Rs 972/Rs 611
Promoter/FPI/DII	55%/13%/16%

Source: NSE | Price as of 22 May 2024

Key financials

Y/E 31 Mar	FY24P	FY25E	FY26E
Total revenue (Rs mn)	20,092	29,741	34,504
EBITDA (Rs mn)	6,748	10,007	11,971
Adj. net profit (Rs mn)	3,920	4,032	5,968
Adj. EPS (Rs)	28.9	29.7	44.0
Consensus EPS (Rs)	28.9	32.9	42.3
Adj. ROAE (%)	15.7	13.8	18.5
Adj. P/E (x)	31.4	30.6	20.7
EV/EBITDA (x)	18.8	13.4	11.6
Adj. EPS growth (%)	2.6	2.9	48.0

Source: Company, Bloomberg, BOBCAPS Research | P – Provisional

Stock performance



Source: NSE

BUY
TP: Rs 320 | ⮝ 24%

GREENPLY INDUSTRIES | Building Materials | 22 May 2024

Misses estimate on weak plywood margin; upbeat outlook

- **MTLM missed our EBITDA estimate by 16% in Q4 on sharper-than-expected contraction in plywood margin on high timber prices**
- **Management guided for a positive outlook on plywood and MDF even in challenging market conditions**
- **Maintain BUY; raise TP by 7% to Rs 320 on strong earnings growth prospects (51% CAGR over FY24-FY26E) and reasonable valuations**

Utkarsh Nopany
research@bobcaps.in

Weak quarter: MTLM missed our estimate for Q4FY24 (Revenue: -4%; EBITDA: -16%) mainly due to sharper-than-expected contraction in plywood segment EBITDA margin (-237bps YoY to 7.9% vs 10% estimate due to high timber prices). Overall, GREENP Revenue/EBITDA grew by 40%/28% YoY in Q4.

Key highlights: Despite challenging market conditions, MTLM reported (a) healthy plywood volume growth (+10.6% YoY; 5Y CAGR: +3.8%); (b) ramp-up of new MDF plant capacity (to 76% in Q4FY24 from 70% in Q3FY24) with a slight improvement in MDF segment margin (+60bps QoQ to 14.1%); and net debt stood at Rs 5.0bn in Mar'24 vs Rs 7.3bn in Dec'23 due to the divestment of a 51% stake in the loss-making subsidiary in Gabon.

Guidance: The company aims to grow its plywood volumes at 8-10% YoY in FY25 and improve EBITDA margin by 50-75bps in FY25. It expects plywood EBITDA margin to improve further to 10%+ level over the next 2-3 years. The company aims to increase its MDF sales volume by 60% YoY in FY25 and EBITDA margin to 15-16% in FY25 from 14.1% in Q4FY24. Management expects the MDF segment EBITDA margin to improve to 18-20% over the medium term. The furniture fittings division is expected to start generating revenue from Q2FY25 and to report loss in FY25 due to the first year of operations; expect good ramp up in FY26 with positive PAT in FY26; and ~Rs 2bn of revenue with healthy EBITDA margin in FY27.

Maintain BUY; raise TP by 7% to Rs 320: We maintain our BUY rating on the stock as we see strong earnings growth prospects (EPS estimated to grow at 51% CAGR over FY24-FY26E), improving return ratios (ROE projected to improve to 17.4% in FY26 from 10.6% in FY24), and reasonable valuation (trades at 24.7x on 1Y forward P/E vs 5Y average of 22.7x). We have reduced our EPS estimates by 2.9%/3.8% for FY25/FY26 based on weak Q4FY24 result, but we have increased our TP by 7% to Rs 320 (Rs 300 earlier) as we roll forward our valuation from Sep'25 to Mar'26. We retain our target P/E of 25x on Mar'26E EPS.

Key changes

Target	Rating
▲	◀ ▶

Ticker/Price	MTLM IN/Rs 257
Market cap	US$ 387.6mn
Free float	48%
3M ADV	US$ 1.4mn
52wk high/low	Rs 285/Rs 149
Promoter/FPI/DII	52%/2%/33%

Source: NSE | Price as of 22 May 2024

Key financials

Y/E 31 Mar	FY24A	FY25E	FY26E
Total revenue (Rs mn)	21,799	24,461	27,431
EBITDA (Rs mn)	1,868	2,528	3,054
Adj. net profit (Rs mn)	752	1,210	1,718
Adj. EPS (Rs)	6.1	9.8	13.9
Consensus EPS (Rs)	6.1	11.2	15.1
Adj. ROAE (%)	11.1	15.8	19.0
Adj. P/E (x)	42.3	26.3	18.5
EV/EBITDA (x)	14.9	10.4	8.9
Adj. EPS growth (%)	(23.7)	60.9	42.0

Source: Company, Bloomberg, BOBCAPS Research

Stock performance



Source: NSE

NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA ("US") OR IN OR INTO ANY OTHER JURISDICTION IF SUCH AN ACTION IS PROHIBITED BY APPLICABLE LAW.

Disclaimer

Name of the Research Entity: **BOB Capital Markets Limited**
Registered office Address: **1704, B Wing, Parinee Crescenzo, G Block, BKC, Bandra East, Mumbai 400051**
SEBI Research Analyst Registration No: **INH000000040 valid till 03 February 2025**
Brand Name: **BOBCAPS**
Trade Name: **www.barodaetrade.com**
CIN: **U65999MH1996GOI098009**

Logo:

Investments in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Recommendation scale: Recommendations and Absolute returns (%) over 12 months

BUY – Expected return >+15%

HOLD – Expected return from -6% to +15%

SELL – Expected return <-6%

Note: Recommendation structure changed with effect from 21 June 2021

Our recommendation scale does not factor in short-term stock price volatility related to market fluctuations. Thus, our recommendations may not always be strictly in line with the recommendation scale as shown above.

Analyst certification

Each of the analysts mentioned in this research report certify, with respect to the sections of the report for which they are responsible, that (1) all of the views expressed in this report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOB Capital Markets Limited (BOBCAPS).

Important disclosures

This product is a compilation of previously published research notes. To view the complete report along with the associated Analyst certifications and Company-specific disclosures, please click on the hyperlink accompanying each excerpt.

General disclaimers

BOBCAPS is engaged in the business of Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. BOBCAPS research reports follow rules laid down by Securities and Exchange Board of India and individuals employed as research analysts are separate from other employees who are performing sales trading, dealing, corporate finance advisory or any other activity that may affect the independence of its research reports.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities — that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.

Other disclosures

BOBCAPS does not have any financial interest in the subject company. BOBCAPS does not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS is not engaged in any market making activities for the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.

Other disclaimers

BOBCAPS and MAYBANK (as defined below) make no representation or warranty, express or implied, as to the accuracy or completeness of any information obtained from third parties and expressly disclaim the merchantability, suitability, quality and fitness of this report. The information in this report has not been independently verified, is provided on an "as is" basis, should not be relied on by you in connection with any contract or commitment, and should not be used as a substitute for enquiries, procedures and advice which ought to be undertaken by you. This report also does not constitute an offer or solicitation to buy or sell any securities referred to herein and you should not construe this report as investment advice. All opinions and estimates contained in this report constitute BOBCAPS's judgment as of the date of this report and are subject to change without notice, and there is no obligation on BOBCAPS or MAYBANK to update this report upon issuance. This report and the information contained herein may not be reproduced, redistributed, disseminated or copied by any means without the prior consent of BOBCAPS and MAYBANK.

To the full extent permitted by law neither BOBCAPS, MAYBANK nor any of their respective affiliates, nor any other person, accepts any liability howsoever arising, whether in contract, tort, negligence, strict liability or any other basis, including without limitation, direct or indirect, special, incidental, consequential or punitive damages arising from any use of this report or the information contained herein. By accepting this report, you agree and undertake to fully indemnify and hold harmless BOBCAPS and MAYBANK from and against claims, charges, actions, proceedings, losses, liabilities, damages, expenses and demands (collectively, the "**Losses**") which BOBCAPS and/or MAYBANK may incur or suffer in any jurisdiction including but not limited to those Losses incurred by BOBCAPS and/or MAYBANK as a result of any proceedings or actions brought against them by any regulators and/or authorities, and which in any case are directly or indirectly occasioned by or result from or are attributable to anything done or omitted in relation to or arising from or in connection with this report.

Distribution into the United Kingdom ("UK"):

This research report will only be distributed in the United Kingdom, in accordance with the applicable laws and regulations of the UK, by Maybank Securities (London) Ltd) ("**MSL**") who is authorised and regulated by the Financial Conduct Authority ("FCA") in the United Kingdom (MSL and its affiliates are collectively referred to as **"MAYBANK**"). BOBCAPS is not authorized to directly distribute this research report in the UK.

This report has not been prepared by BOBCAPS in accordance with the UK's legal and regulatory requirements.

This research report is for distribution only to, and is solely directed at, selected persons on the basis that those persons: (a) are eligible counterparties and professional clients of MAYBANK as selected by MAYBANK solely at its discretion; (b) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended from time to time (the "Order"), or (c) fall within Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc. as mentioned in the stated Article) of the Order; (all such persons together being referred to as "relevant persons").

This research report is directed only at relevant persons and must not be acted on or relied on by any persons who are not relevant persons. Any investment or investment activity to which this material relates is available only to relevant persons and will be engaged in only with relevant persons.

The relevant person as recipient of this research report is not permitted to reproduce, change, remove, pass on, distribute or disseminate the data or make it available to third parties without the written permission of BOBCAPS or MAYBANK. Any decision taken by the relevant person(s) pursuant to the research report shall be solely at their costs and consequences and BOBCAPS and MAYBANK shall not have any liability of whatsoever nature in this regard.

No distribution into the US:

This report will not be distributed in the US and no US person may rely on this communication.

Other jurisdictions:

This report has been prepared in accordance with SEBI (Research Analysts) Regulations and not in accordance with local regulatory requirements of any other jurisdiction. In any other jurisdictions, this report is only for distribution (subject to applicable legal or regulatory restrictions) to professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions by Maybank Securities Pte Ltd. (Singapore) and / or by any broker-dealer affiliate or such other affiliate as determined by Malayan Banking Berhad.

If the recipient of this report is not as specified above, then it should not act upon this report and return the same to the sender.

By accepting this report, you agree to be bound by the foregoing limitations.